Aerie Pharmaceuticals commences Phase 2 clinical trial of AR-1105
Category: #health  By Mateen Dalal  Date: 2019-03-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Aerie Pharmaceuticals commences Phase 2 clinical trial of AR-1105

AR-1105 is an intravitreal, fully bio-erodible PRINT-manufactured implant that releases steroid dexamethasone.

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company, has reportedly initiated the Phase 2 clinical trial evaluating AR-1105 for investigation of its dexamethasone intravitreal implant in patients suffering from macular edema caused by retinal vein occlusion (RVO).

Up to 45 patients will be enrolled for this Phase 2 study and trial will be conducted at approximately 20 centers in United States. The primary endpoint of this study is safety, tolerability, and efficacy of AR-1105 dexamethasone intravitreal implant. The estimated date of completion is January 2020.

As per a press release by Aerie Pharmaceuticals, there will be two stages in this study. In first stage, up to 5 patients will be enrolled to receive CF-1 and in stage-2, up to 40 randomized patients will receive either CF-1 or CF-2. CF-2 delivers same dose of dexamethasone for a longer period. This study has been made available at www.clinicaltrials.gov.

Chairman and Chief Executive Officer, Vicente Anido, Jr., Ph.D., cited that they are building a concept study for AR-1105 and retina portfolio based on technology of DSM being developed with bio-erodible polymers and platform of PRINT manufacturing.

He further stated that they are expecting the trial to allow optimization of AR-1105 for achieving their objective in Phase 3 studies. They also have plans to file an investigational new drug, AR-13503 implant, which is a bio-erodible implant delivering Rho kinase/Protein kinase C inhibitor for treating wet-related macular degeneration and diabetic macular edema.

AR-1105 is an intravitreal, fully bio-erodible PRINT-manufactured implant that releases steroid dexamethasone. It is administered by a commonly used in-office treatment called Intravitreal Injection.

For the record, Aerie Pharmaceuticals is a clinical-stage, public pharmaceutical company, concentrated on discovery, development, and commercial aspects of first-in-class therapies for treating patients with eye diseases. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Google’s business intelligence platform Looker collabs with Tableau
Google’s business intelligence platform Looker collabs with Tableau
By Mateen Dalal

Google Cloud Platform has recently revealed that its business intelligence platform, Looker has been integrated with Tableau, empowering users of both the platforms to benefit from the different features offered by each. For starters, Google Cloud a...

HR tech firm Personio ropes in $270 million in latest financing round
HR tech firm Personio ropes in $270 million in latest financing round
By Mateen Dalal

Personio, a HR software provider targeting small and medium sized businesses, has attained a $270 million investment in the wake of high demand for its services. With the latest Series E round of funding, Personio's valuation roses to $6.3 billi...

New Zealand prepares to deal with potential surge in COVID-19 cases
New Zealand prepares to deal with potential surge in COVID-19 cases
By Mateen Dalal

New Zealand is preparing for an increase in Covid-19 cases after registering 94 new infections over the weekend, with pandemic modelers predicting that if the government continues on its present path, new cases would rapidly exceed 100 per day. Epid...